Dr. Reddy's Laboratories Limited
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Erez Israeli
- Full Time Employees
- 27,048
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 8-2-337, Road No. 3 Hyderabad India 500034
- IPO Date
- Apr 11, 2001
- CIK
- 0001135951
- Website
- drreddys.com
- Similar Companies
- Business
- Dr. Reddy's Laboratories Limited is an Indian multinational pharmaceutical company headquartered in Hyderabad, India, and founded in 1984 that develops, manufactures, and markets a broad portfolio of products including active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars, differentiated formulations, over-the-counter (OTC) medicines, and innovative prescription drugs across therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, dermatology, anti-infectives, and critical care; key offerings encompass over 190 formulations like omeprazole (Omez), rabeprazole (Razo), rituximab biosimilars, toripalimab for nasopharyngeal carcinoma, lenacapavir for HIV under license from Gilead Sciences, and APIs including abiraterone acetate, canagliflozin, ciprofloxacin hydrochloride, ramipril, ibuprofen, sertraline hydrochloride, and naproxen sodium. The company operates globally in over 66 countries with a strong emphasis on North America, Europe, India, Russia, emerging markets, and regions including China, Japan, Vietnam, Myanmar, and South Africa, serving patients, pharmacies, hospitals, and other pharmaceutical firms through vertically integrated facilities compliant with US FDA, EMA, and other regulators. In recent developments, Dr. Reddy's completed the acquisition of Haleon's global nicotine replacement therapy (NRT) portfolio excluding the US for GBP 458 million in September 2024 to bolster its OTC consumer healthcare business, entered a June 2025 collaboration with Alvotech to co-develop, manufacture, and commercialize a pembrolizumab (Keytruda) biosimilar for global markets sharing costs and responsibilities, expanded partnerships including with Advanz Pharma for additional biosimilars and with Nestle India via joint venture for capabilities enhancement, and launched products such as the first UK-approved bevacizumab biosimilar for multiple cancers, Skorolox (loxoprofen) in Russia, and a RSV preventive for infants in India while advancing complex injectables, cell/gene therapies, and patient support programs like Purple Health.
NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY
Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push
Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada
Dr. Reddy's Laboratories Q4 Earnings Call Highlights
Dr. Reddy's Q4 Earnings and Revenues Miss Estimates, Stock Down
Dr. Reddy's Laboratories Limited (RDY) Q4 2026 Earnings Call Transcript
Indian drugmaker Dr Reddy's posts quarterly profit slump
AMPH vs. RDY: Which Stock Should Value Investors Buy Now?
Canada Approves Dr. Reddy's Generic Version of Novo Nordisk's Ozempic
Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada
India's Generic Wave Hits Ozempic And Wegovy As Prices Drop Sharply
3 Generic Drug Stocks to Watch Despite Industry Headwinds
Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
Dr. Reddy’s Laboratories Ltd $RDY Shares Acquired by Bessemer Group Inc.
Dr. Reddy’s Laboratories Q3 Earnings Call Highlights
Dr. Reddy's Q3 Earnings Match Estimates, Revenues Rise Y/Y
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript
Dr. Reddy's Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape
Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa